These compounds can be used to treat hypertension, pulmonary hypertension (HAP),congestive heart failure, conditions resulting from excessive water retention, cardiovascular disease, diabetes, oxidative stress, endothelial dysfunction, cirrhosis, pre-eclampsia, osteoporosis, or kidney disease. Claim 1: A compound having the formula (1) or a pharmaceutically acceptable salt thereof, wherein X is O or NR⁷；the remainder of formula (2) is attached to any carbon atom of the ring to which R¹ and R² are attached； R¹ is hydrogen, -C (O) OR C₁₋₆ alkyl,o -C (O) OH o junto con RShape = O； R2 is hydrogen, or with R1,2. Shape = O； r8308es asphalt c832131；-CD₂-alkyl Cilo,-C₂₋₅-OH alkylene, -C₂₋₅-O-C (O) C₁₋₆-alkyl,-alkylene-aryl C₁₋₆,or -CH₂CH = CH₂；R83099a and r8310a,Hydrogen, deuterium, tar c833212626 are associated with any atom in the carbon circle；-C (O) O-C₁₋₆-alkyl,-C (o) Oh, arilo, O r83099 and r8310a,When they are connected with the same carbon atom, they are equal to o； r8311811 is hydrogen-c832131-832626 tar；-alkylene-aryl C₁₋₆,-C₁₋₆-C-alkylene (O) O-C₁₋₆-alkyl,-Lessor c83218s 83316262-cr83212； r8313； r1830404；-CN, -C (O) O-C₁₋₆-alkyl,-C (o) o-asphalt c8321 and 832626； cr831222； r8313； r183044；-C (O) alquilo C-C (O) O-carbociclo C-C (O) CHF-C (O) CF-C (O) CH₂OH, -C (O) aryl, -C (O) heteroaryl, in which the heteroaryl is a 5- or 6-membered unsaturated ring having 1-4 heteroatoms selected from N, O and S, - C (O) alkylene C₁₋₆OH, -C (O) carbocycle C₃₋₆,-C (O) NH-C (o) NH asphalt c8321；-C (o) NH adamantillo, - C (o) heteromorphic cycle is a single ring composed of 5 to 8 members, including 1 to 4 heteroatoms selected from n, O and s, or a saturated double ring system composed of 7 to 12 members, including 1 to 6 heteroatoms selected from n, O and s；-C (o) n (pitch c832131)；-C (O) NHSO -arilo -SO-alquilo C-SO₂-alkyl C₁₋₆,-SO₂NH (C₁₋₆-alkyl),-So8322jn (c8332131 asphalt) 832626 (c83321131 asphalt)；-SO₂CF₃,-SO₂-aryl, -SO₂-heteroaryl, wherein heteroaryl is a 5- or 6-membered u
